Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3283
Source ID: NCT01028963
Associated Drug: Placebo
Title: A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: Placebo|DRUG: pioglitazone|DRUG: CCX140-B|DRUG: CCX140-B
Outcome Measures: Primary: Subject incidence of adverse events, 28 days | Secondary: Effect on fasting plasma glucose concentration, 28 days
Sponsor/Collaborators: Sponsor: Amgen
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 159
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2010-01
Completion Date: 2010-11
Results First Posted:
Last Update Posted: 2025-03-06
Locations: Auchenflower, Queensland, Australia|Kippa-Ring, Queensland, Australia|Beroun, Czechia|Hlucin, Czechia|Neratovice, Czechia|Novy Jicin, Czechia|Ostrava, Czechia|Pardubice, Czechia|Prague, Czechia|Prelouc, Czechia|Slany, Czechia|Uhersky Brod, Czechia|Unicov, Czechia|Usti nad Labem, Czechia|Basenheim, Germany|Berlin, Germany|Cologne, Germany|Dresden, Germany|Heidelberg, Germany|Mannheim, Germany|Nuremberg, Germany|Saarlouis, Germany|Balatonfuered, Hungary|Budapest, Hungary|Satoraljaujhely, Hungary|Szikszo, Hungary|Christchurch, New Zealand|Wellington, New Zealand
URL: https://clinicaltrials.gov/show/NCT01028963